ArticleHuman genetics2026
ScSpTITH: a rank-correlation framework for robust quantification of multi-dimensional tumor heterogeneity.
Article in Human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intra- and inter-tumoral heterogeneity (ITH) is a fundamental hallmark of cancer, driving spatial, temporal, cellular, and tumor microenvironmental (TME) complexity and critically contributing to therapeutic resistance. Single-cell RNA sequencing (scRNA-seq) provides unprecedented resolution for dissecting tumor heterogeneity; however, its accuracy is severely compromised by pervasive "dropout" artifacts, resulting in zero-inflation rates of 70-95% in typical scRNA-seq datasets. To address this limitation, we introduce ScSpTITH (Single-cell and Spatial Transcriptomic Intra-/inter-Tumoral Heterogeneity), a robust computational framework for quantifying ITH in both scRNA-seq and spatial transcriptomic data. ScSpTITH first selects highly variable genes based on standard deviation to prioritize biologically informative features, and then computes pairwise Spearman rank correlations across cells. This rank-based strategy confers inherent robustness to technical noise, non-normality, and high dropout rates, enabling stable and interpretable quantification of transcriptional heterogeneity. Across diverse cancer and developmental datasets, elevated ScSpTITH scores are strongly associated with active tumor evolution, advanced disease stage, pronounced cellular plasticity, therapeutic resistance, and poor clinical outcomes. ScSpTITH is scalable and flexible, allowing heterogeneity to be quantified across inter-tumoral and intra-tumoral dimensions, including spatial regions, cell populations, and treatment conditions. Collectively, ScSpTITH provides a unified and robust framework for dissecting multi-dimensional heterogeneity in single-cell and spatial transcriptomic studies.
Indexed as
Identifiers
42223713What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.